Compare Southwest Airlines Co (LUV) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Sanofi SA — how do they compare? Southwest Airlines Co trades at $45.71 (market cap $21.97B), while Sanofi SA trades at $43.25 (market cap $104.57B). The key difference: Sanofi SA is far larger — about 4.8× Southwest Airlines Co's market cap, and Sanofi SA pays the higher dividend (5.56%). Which is the better fit depends on your goals.
| LUV | SNY | |
|---|---|---|
Market Cap | $21.97B | $104.57B |
Sector | Industrials | Health |
52-Week High | $54.80 | $52.34 |
52-Week Low | $29.67 | $41.33 |
Enterprise Value | $25.06B | $124.48B |
Dividend Yield | 1.6% | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $47.05, up 0.23% today, with a bullish technical signal and consensus price target of $53.86. Recent Q2 2026 earnings beat expectations with EPS of $0.94 versus $0.51 expected, driven by record revenue. The company maintains a solid liquidity position of $8.73B cash and has declared quarterly dividends of $0.18 per share, with new board appointments signaling strategic focus.
Outlook is positive with projected 2026 net income margin of 2.78% and revenue growth to $30.1B, but risks include fuel cost volatility and competitive pressures. Analyst sentiment is mixed with 42% buy ratings, offering potential upside of 14.5% to the consensus target, though institutional selling by firms like Elliott Management warrants monitoring.
SNY trades at $43.46, up 1.33% today, with neutral technical signals and mixed analyst sentiment. The company reported strong Q2 2026 earnings beats and raised 2026 guidance, driven by Dupixent's performance. Recent approvals for MenQuadfi and Sarclisa injector provide growth catalysts, while pipeline setbacks like amlitelimab discontinuation present challenges. Valuation metrics show a P/E of 23.22 and P/S of 1.87, with improving profit margins from 12.55% in 2024 to 16.72% in 2025.
SNY offers steady dividend income with positive earnings momentum, though pipeline execution risks and competitive pressures remain concerns. The stock presents value for income-focused investors with upside potential from new drug approvals, but requires monitoring of CEO Garijo's strategic initiatives and Dupixent's long-term market position against biosimilar threats post-2031.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
